PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Becton, Dickinson and Company

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BD MAX™ MRSA XT Assay with eXTended Detection Technology Receives FDA Clearance - New Laboratory Test Helps Hospitals Detect Newly Emerging Strains of Drug-Resistant Superbug - BD.com
BD MAX™ MRSA XT Assay with eXTended Detection Technology Receives FDA Clearance

 

NewswireToday - /newswire/ - Baltimore, MD, United States, 2014/01/13 - New Laboratory Test Helps Hospitals Detect Newly Emerging Strains of Drug-Resistant Superbug - BD.com. NYSE: BDX

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, announced today it has received FDA clearance to market the BD MAX™ MRSA XT Assay for use on the fully-automated BD MAX™ System. This is the second assay from BD Diagnostics capable of detecting newly emerging MRSA strains with the novel mecC gene. Launched in 2013, the BD MAX™ StaphSR Assay reports results for both Staphylococus aureus (SA) and methicillin-resistant Staphylococus aureus (MRSA) and was the first commercially available assay in the U.S. to detect mecC strains of MRSA. Both assays use eXTended Detection Technology to identify a broad range of SA strains including mecA and mecC dropout mutants and new strains of MRSA that may not be detected by other assays.

“Assay design is critical to detect MRSA accurately and ensure appropriate infection control interventions are applied,” said Dr. Patrick Murray, Worldwide Director of Scientific Affairs, BD Diagnostics Diagnostic Systems. “The BD MAX MRSA XT Assay helps improve patient safety by providing hospitals with a new solution to detect the latest strains of this drug-resistant superbug.”

Molecular assays for MRSA are used in active surveillance programs to identify colonized patients rapidly. Active surveillance is a proven strategy to reduce transmission in healthcare settings and helps prevent infection in vulnerable patients.[i] Inaccurate detection may contribute to uncontrolled transmission of MRSA and inappropriate use of healthcare resources.With many commercial assays, SA strains carrying SCCmec where the mecA gene is absent (commonly called “dropout mutants”) may be incorrectly classified as MRSA. These false positive results can lead to unnecessary and expensive isolation and treatment of patients.[ii] MRSA strains with the newly emerging mecC gene account for nearly three percent of all new MRSA cases[iii] in some communities but cannot be detected by all assays.[iv] These false negative results can lead to uncontrolled transmission of undetected strains of MRSA.[v]

As a pioneer in healthcare-associated infections (HAIs), BD has the insights and expertise to provide hospitals innovative solutions that can improve patient care. The BD MAX MRSA XT Assay is the latest milestone demonstrating BD’s commitment to providing advanced assays to detect and prevent HAIs. Other HAI assays available on the BD MAX System include BD MAX™ Cdiff for the detection of toxigenic Clostridium difficile DNA, and BD MAX StaphSR. BD MAX™ HAI Solutions combine efficiency through system automation with the flexibility to perform multiple HAI assays in the same run, allowing hospital laboratories to customize testing in response to current and future challenges in the fight against HAIs.

About BD

BD (bd.com) is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives” by advancing the quality, accessibility, safety and affordability of healthcare around the world.

[i] Jain et al., N Engl J Med 2011;364:1419-30. Veterans Affairs Initiative to Prevent Methicillin-Resistant Staphylococcus aureus Infections
[ii] Blanc et al., JCM 2011;49:722-724. High Proportion of Wrongly Identified Methicillin-Resistant Staphylococcus aureusCarriers by Use of a Rapid Commercial PCR Assay Due to Presence of Staphylococcal Cassette Chromosome Element Lacking the mecA Gene.
[iii] Petersen et al., Epidemiology of methicillin-resistant Staphylococcus aureus carrying the novel mecC gene in Denmark corroborates a zoonotic reservoir with transmission to humans Clin Micro Infect 2013;19:E16-E22
[iv] Shore et al., Antimicrobial Agents and Chemotherapy. 2011;55:3765-3773
[v] Worby et al., Am J Epidemiology advanced access published online April 16, 2013. Estimating the Effectiveness of Isolation and Decolonization Measures in Reducing Transmission of Methicillin-resistant Staphylococcus aureus in Hospital General Wards

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Becton, Dickinson and Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BD MAX™ MRSA XT Assay with eXTended Detection Technology Receives FDA Clearance

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

BD | eXTended Detection Tech
Publisher Contact: Jamie Yacco - BD.com 
201-847-4796 Jamie_Yacco[.]bd.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Becton, Dickinson and Company / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)